Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

NINDS Acute Disseminated Encephalomyelitis Information Page

Synonym(s):   Postinfectious Encephalomyelitis, Immune-Mediated Encephalomyelitis

Table of Contents (click to jump to sections)


Listen to this page using ReadSpeaker


What is Acute Disseminated Encephalomyelitis?

Acute disseminated encephalomyelitis (ADEM) is characterized by a brief but widespread attack of inflammation in the brain and spinal cord that damages myelin – the protective covering of nerve fibers.  ADEM often follows viral or bacterial infections, or less often, vaccination for measles, mumps, or rubella.  The symptoms of ADEM appear rapidly, beginning with encephalitis-like symptoms such as fever, fatigue, headache, nausea and vomiting, and in the most severe cases, seizures and coma.  ADEM typically damages white matter (brain tissue that takes its name from the white color of myelin), leading to neurological symptoms such as visual loss (due to inflammation of the optic nerve) in one or both eyes, weakness even to the point of paralysis, and difficulty coordinating voluntary muscle movements (such as those used in walking).  ADEM is sometimes misdiagnosed as a severe first attack of multiple sclerosis (MS), since the symptoms and the appearance of the white matter injury on brain imaging may be similar.  However, ADEM has several features which differentiate it from MS.  First, unlike MS patients, persons with ADEM will have rapid onset of fever, a history of recent infection or immunization, and some degree of impairment of consciousness, perhaps even coma; these features are not typically seen in MS.  Children are more likely than adults to have ADEM, whereas MS is a rare diagnosis in children.  In addition, ADEM usually consists of a single episode or attack of widespread myelin damage, while MS features many attacks over the course of time. Doctors will often use imaging techniques, such as MRI (magnetic resonance imaging), to search for old and new lesions (areas of damage) on the brain.  The presence of older brain lesions on MRI suggest that the condition may be MS rather than ADEM, since MS can cause brain lesions before symptoms become obvious.  In rare situations, a brain biopsy may be necessary to differentiate between ADEM and some other diseases that involve inflammation and damage to myelin.. 

Is there any treatment?

Treatment for ADEM is targeted at suppressing inflammation in the brain using anti-inflammatory drugs. Most individuals respond to several days of intravenous corticosteroids such as methylprednisolone, followed by oral corticosteroid treatment.  When corticosteroids fail to work, plasmapheresis or intravenous immunoglobulin therapy are possible secondary treatment options that are reported to help in some severe cases.  Additional treatment is symptomatic and supportive. 

What is the prognosis?

Corticosteroid therapy typically helps hasten recovery from most ADEM symptoms.  The long-term prognosis for individuals with ADEM is generally favorable.  For most individuals, recovery begins within days, and within six months the majority of ADEM patients will have total or near total recoveries.  Others may have mild to moderate lifelong impairment ranging from cognitive difficulties, weakness,  loss of vision, or numbness.  Severe cases of ADEM can be fatal but this is a very rare occurrence.  ADEM can recur, usually within months of the initial diagnosis, and is treated by restarting corticosteroids.  A small fraction of individuals who are initially diagnosed as having ADEM can go on to develop MS, but there is currently no method or known risk factors to predict whom those individuals will be. 

What research is being done?

The National Institute of Neurological Disorders and Stroke (NINDS) and other institutes of the National Institutes of Health (NIH) conduct research related to ADEM in laboratories at the NIH, and also support additional research through grants to major medical institutions across the country. Much of this research focuses on finding better ways to prevent, treat, and ultimately cure demyelinating disorders such as ADEM.

NIH Patient Recruitment for Acute Disseminated Encephalomyelitis Clinical Trials

Organizations

Column1 Column2
United Leukodystrophy Foundation
224 North 2nd Street, Suite 2
DeKalb, IL   60115
office@ulf.org
http://www.ulf.org
Tel: 815-748-3211 800-728-5483
Fax: 815-748-0844

National Organization for Rare Disorders (NORD)
55 Kenosia Avenue
Danbury, CT   06810
orphan@rarediseases.org
http://www.rarediseases.org
Tel: 203-744-0100 Voice Mail 800-999-NORD (6673)
Fax: 203-798-2291

Publicaciones en Español


Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892



NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.

Last updated February 14, 2014